Underweight MDT: Pre-commit 20-25% trim with conditional 10% tranche on $87.80 breakdown; anchor core to $87.50 stop
Underweight MDT based on cumulative alpha drag from four prior HOLDs (-2.2% to -3.2% combined) demonstrating the pattern that HOLD rating is obligated to address; technical setup shows MACD histogram -0.49 for 11 sessions, lower Bollinger Band breach on 1.4x volume (10.5M), VWAP at $92.46 overhead resistance, and $0.33 buffer to 50 SMA with 200 SMA 74 cents below; fundamental risk of tax rate normalization from 16.3% to 31% compressing forward EPS from $6.41 to ~$5.50. Calibrated 20-25% trim (not full exit) preserves dividend carry, Q2 FY27 optionality, and structural pillars (FCF coverage, 47+ consecutive raises, LigaSure-Hugo clearance) while applying 9/18 and 9/21 lessons on pre-committed sizing discipline.
| Position | Action |
|---|---|
| Primary tranche: close in $89-91 range | Sell 10-15% of MDT exposure over 3-5 sessions into the bid |
| Bear trigger: close below $87.80 | Sell additional 10% (contingent tranche) |
| Bull trigger: close above $89.50 with MACD histogram contracting AND RSI >40 | Cancel the 10% contingent tranche and flatten (do not add) |
| Retain core position: 75-80% of MDT exposure | Anchor to trader's $87.50 stop loss |
Medtronic's 41% earnings inflection, raised guidance, 13.94x forward P/E, and 3.17% dividend yield create a mispricing at the 50/200 SMA support cluster, with the only large-cap device name holding value while peers collapse.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 91.80 | bearish |
| close_50_sma | 88.97 | neutral |
| close_200_sma | 88.23 | neutral |
| macd | 0.59 | bearish |
| macds | 1.09 | bearish |
| macdh | -0.49 | bearish |
| rsi | 43.00 | neutral |
| boll | 91.97 | bearish |
| boll_ub | 94.45 | neutral |
| boll_lb | 89.49 | bearish |
| atr | 2.15 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close >$89.50 with MACD histogram contracting AND RSI >40
Then: Cancel-and-flatten: cancel bear trigger, do not sell additional shares
↩ rebuts: “Bear treats TTM P/E of 22.21x as fairly valued”
EV: +5.3% to $94 (first target) · concedes: 13-session pullback is real and cannot be ignored; RSI 43 is not yet oversold — more room to fall; VWMA gap of -$3.16 is a single-session overshoot that needs confirmation; 50 SMA is thin support ($0.33 buffer); Wall Street split on whether growth acceleration supports re-rating; USD strength is a mild headwind on Ireland-domiciled reporting; Volume-weighted sellers temporarily in control
The "inflection" is a single-quarter anomaly driven by a depressed base and tax rate quirk, the forward P/E requires unrealistic 59% earnings growth, technicals show confirmed breakdown with minimal support, and the balance sheet's $53.42B in goodwill creates impairment risk in a sector where BSX's collapse signals contagion rather than competitive outperformance.
EV: -$10 to -$15 (6-16% downside from $89.30 to $76-$80) · concedes: LigaSure FDA clearance is real and tactically positive; MDT is the only large-cap device name holding value (relative performance); Q1 FY27 operating income did grow +21.1%; Revenue did grow +13.7%
→ vs conservative: Technical breakdown signals (MACD histogram negative 0.49, close below lower Bollinger band, VWMA overhead resistance) are treated as static distribution signals rather than an inflection point indicating a coiled spring setup
→ vs conservative: Relative positioning as the only large-cap device name holding value while peers bleed (BSX down 55%, ISRG off 12%, Abbott down 17%) contradicts the fragile setup characterization
→ vs conservative: Goodwill-heavy balance sheet concern (57% intangibles) ignores $5.4 billion annual FCF and $5.1 billion total shareholder returns
→ vs conservative: Tax normalization to 31% compressing earnings still yields ~$5.50 EPS and ~16x forward P/E on a 3.17% yielding defensive franchise
→ vs neutral: Q1 beat, guidance raise, and Hugo LigaSure FDA clearance are textbook catalysts that should re-rate the multiple - waiting for confirmation is backwards when the catalysts already happened
→ vs neutral: The resolution IS the trade; the framework is about being positioned with defined triggers rather than waiting on the sidelines
| vwma | 92.46 | bearish |
Support: 89.49 · 88.97 · 88.23 | Resistance: 94.45 · 91.97 · 91.8
MDT exhibits a bearish near-term technical setup with price closing $0.19 below the lower Bollinger band at $89.49, a deepening MACD histogram at -0.49 (11-session bearish crossover), and the 10 EMA ($91.80) now $2.50 above price — confirming near-term momentum has rolled. The critical inflection is the 50 SMA at $88.97, only $0.33 below the close; a decisive daily close below $88.97 would flip the medium-term bias negative. Major support clusters at the 50/200 SMA confluence ($88–$89) and the 200 SMA ($88.23) represent key structural floors. ATR of $2.15 suggests using 1×–2×ATR stops ($2–$4) for risk management. The overall rating is HOLD pending either a confirmed break below $88.97 (shifts to SELL) or recovery above $92.00 with volume confirmation (shifts to BUY).
Market Cap
$114.23 B
Implied Share Price
~$89.20
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$89.00
200-Day MA
$89.15
Trailing P/E
22.21x
Forward P/E
13.94x
Forward EPS
$6.41
TTM EPS
$4.02
PEG Ratio
1.63
Price-to-Book
2.28x
Book Value
$39.24
Dividend Yield
3.17%
Beta
0.574
Q1 FY27 Revenue
$9.756 B
Q1 FY27 Gross Profit
$6.340 B
Q1 FY27 Operating Income
$1.836 B
Q1 FY27 Net Income
$1.470 B
Q1 FY27 Diluted EPS
$1.14
Q1 FY27 Revenue Growth YoY
+13.7%
Revenue (TTM)
$37.54 B
Gross Margin (TTM)
65.3%
EBITDA (TTM)
$10.41 B
EBITDA Margin
27.7%
Operating Margin (TTM)
19.33%
Net Income (TTM)
$5.23 B
Net Profit Margin (TTM)
13.93%
Cost of Revenue (Q1 FY27)
$3.42 B
Cost of Revenue %
35.0%
R&D (Q1 FY27)
$0.77 B
R&D %
7.9%
SG&A (Q1 FY27)
$3.20 B
SG&A %
32.8%
Operating Expense (Q1 FY27)
$4.50 B
Operating Expense %
46.2%
Effective Tax Rate (Q1 FY27)
16.3%
Total Assets (Jul-26)
$93.31 B
Total Liabilities (Jul-26)
$42.46 B
Total Equity (Jul-26)
$50.85 B
Total Debt (Jul-26)
$28.15 B
Cash + ST Investments (Jul-26)
$8.82 B
Net Debt
$26.41 B
Working Capital
$12.59 B
Current Ratio
2.07x
Debt / Equity
55.4%
Goodwill
$43.19 B
Intangibles
$10.24 B
Total Intangible Assets
$53.42 B
Tangible Book Value
$-3.19 B
Diluted Shares Outstanding
~1.285 B
Q1 FY27 Operating Cash Flow
$1.79 B
Q1 FY27 CapEx
($0.50) B
Q1 FY27 Free Cash Flow
$1.29 B
Q1 FY27 Dividends
($0.92) B
Q1 FY27 Buybacks
($0.27) B
FCF (TTM)
$5.41 B
FCF Margin
14.4%
Annual Dividends (TTM)
~$3.66 B
Annual Buybacks (TTM)
~$1.50 B
Annual M&A Spend (TTM)
~$1.66 B
ROE
10.65%
ROA
5.12%
Dividend Payout Ratio
60-70%
Interest Expense
~$186M/quarter
Strengths
Concerns
Medtronic is a mega-cap ($114.23B) medical device leader trading at attractive 13.94x forward P/E with a 3.17% dividend yield, supported by a Q1 FY27 earnings inflection (+41% YoY EPS growth). The company generates robust FCF ($5.41B TTM, 14.4% margin) and maintains a strong balance sheet with declining net debt ($26.41B), though heavy intangible assets ($53.42B) constrain return metrics. Capital allocation prioritizes shareholder returns (~68% of FCF to dividends, ~22% to buybacks) while funding bolt-on M&A (~$1.66B annually) to augment organic growth from new product cycles.
Macro: Fed policy: 96% probability of ZERO Fed rate cuts in 2026 (Polymarket, $8.5M volume, +1.7pp WoW) — "higher for longer" regime; Fed described as "more willing to tolerate economic pain than investors expected." US recession by end-2026: 8% (down 4pp WoW) — very low priced risk; UK recession 12%, Japan recession 4%. Gold settling lower on rising USD and yields confirms hawkish Fed narrative. Supply-shock pressures from oil/tariffs cited as persistent cost inputs. For MDT specifically: defensive, dividend-paying large caps benefit when rates stay high and recession risk is contained; MDT called out in defensive dividend stock coverage; FX headwind from strong dollar on ~40%+ non-U.S. revenue (Ireland-domiciled reporter).